Office Of Clinical Trials. Christine Nelson, RN, BSN, MBA, CCRC
|
|
|
- Geraldine Ross
- 6 years ago
- Views:
Transcription
1 Office Of Clinical Trials Christine Nelson, RN, BSN, MBA, CCRC
2 OCT Mission Statement The mission of the Office of Clinical Trials (OCT) is to serve the Carolina research community by improving the quality of support by facilitating and streamlining the startup, conduct and administration of clinical trials. In support of that mission, the OCT strives to: 1) Standardize the processes for clinical trials to ensure consistency, efficiency, and compliance with Federal, State and University requirements; 2) Provide educational opportunities to research faculty and staff; 3) Facilitate regulatory knowledge and support to investigators and clinical research professionals to enhance compliance with federal and institutional requirements; 4) Identify and/or support development of new clinical research opportunities in collaboration with our clinical research teams; 5) Encourage interdisciplinary collaboration for clinical research and incorporate available resources throughout the University and UNC Health Care.
3 Clinical Trial Quality Assurance Program Routine Reviews Post Approval Reviews Directed Reviews OHRE Department head Vice Chancellor for Research Preparation for External Reviews FDA Sponsor Audits Assist with external audits/inspections
4 Clinical Trial Quality Assurance Program Conducted 57 post approval reviews Assisted with 5 FDA inspection Conducted 3 root cause analyses (RCA) with departments to assist with the development of Corrective and preventative Action Plans (CAPA) Assisted with draft communications with the FDA Collaborated with two prominent Clinical Research Organizations to improve the quality of the clinical trials conducted at UNC
5 Clinical Trial Quality Assurance Program Forms and checklists available on our website Track GCP training Will begin tracking and trending sponsor monitor follow up reports Draft policies
6 PS Project ID Set up Conduct compliance review prior to PS project ID set up by OSR GCP training completed and current IRB approval IPF submission with internal budget COI training, disclosure and review complete Congruency of BCA, CTA and ICF
7 Clinical Trial Billing Compliance Review and assistance with the Billing Coverage Analysis Ensures consistency of BCA, CTA and ICF prior to account set up Research 100 classes, monthly Now available CITI training on Clinical Trial Billing Compliance Clinical Trial Billing reviews to start soon
8 ClinicalTrials.gov Support with registration and results reporting for ClinicalTrials.gov Alerts investigators when trials appear on the problem report for late results reporting
9 ClinicalTrials.gov Final rule announced September 16, 2016 Effective date January 18, 2017, 90 days to come into compliance April 18, 2017 Clarification and expansion of the definition of an applicable clinical trial Clarified responsible party Clarified and increased the results reporting Need full protocol, including a statistical Analysis plan NIH can withhold funding if there is failure to report results
10 CRMS Support Provide customer and technical support for CRMS Proactively troubleshoot issues Perform Quality Assurance/Quality Control of the CRMS System and development measures. Training Research 100 One on one
11 Scientific Review Committee Need for the separation of the scientific review from the IRB review Administrative support Require full protocol with statistical analysis plan In line with new NIH and CT.gov final rule Goal to improve turn around times for IRB review Improve the quality of protocols SRC will no longer review industry sponsored protocols
12 Support New research Opportunities Clinical research staffing is key to the success of the investigator and the study Investigators may have a desire to lead clinical trials but lack the required study support resources due to difficulty in recruiting, retaining and efficiently onboarding staff. UNC has launched a pilot program with a commercial partner to offer site-management services to investigators and departments with limited infrastructure.
13 Future Prepaid card for study subject payments IND/IDE registration with OCT Policy on delegation of tasks Enterprise wide clinical trials management system
14 Last thought
15 Questions
Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals
ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction
10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.
Wednesday October 10, 2012 Please be sure to sign in and take copies of each handout. 1 Alicia Joy, IRB 2 FH Office of Research Administration Christina Jackson, BSN, RN, CCRC, CHRC 1 ClinicalTrials.gov
DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH
DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH TITLE: SOP #: QA-706 Page: 1 of 7 Applicable Regulations & Guidelines: 21 CFR 312.60 General Responsibilities of
ClinicalTrials.gov REGISTRATION REQUIREMENTS
ClinicalTrials.gov REGISTRATION REQUIREMENTS Background: What is it? ClinicalTrials.gov is a public registry that provides easy access to information on clinical studies, both clinical trials and observational
Human Subjects Research Policy Update. Naomi Coll Director of Research Policy and Compliance
Human Subjects Research Policy Update Naomi Coll Director of Research Policy and Compliance Major Policy Updates 1. Activities that meet the HHS or FDA definition of human subjects research are subject
Terry Sousa UMass Medical School PRS Administrator for Clinicaltrials.gov
Terry Sousa UMass Medical School PRS Administrator for Clinicaltrials.gov What is ClinicalTrials.gov? National registry of federally and privately supported research studies Why register and report results?
ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
FDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
Sponsor-Investigator Responsibilities In Clinical Trials
In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.
Human Research Protection Program Policy
Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving
Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
Research 101. Health Care Compliance Association Regional Conference Columbus, Ohio May 8, 2015
Research 101 Health Care Compliance Association Regional Conference Columbus, Ohio May 8, 2015 Jennifer Lanter, MSPH, BSN, RN, CCRC Director, Research & Special Billing Office Agenda Research Compliance
GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018
1 GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018 Sumitra Sachidanandan GCP Inspection Consultant Clinical Trials Branch Health Products Regulation Group Health Sciences Authority Singapore
Mini Rounds Wednesday, May 21, 2014
Mini Rounds Wednesday, May 21, 2014 2014 Updates New Staff and Current Vacancies Standing Meetings Reminder All Staff Announcements CRCO Inbox Central Office Central Office move Roles and Responsibilities
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
Effectively Preparing for and Responding to an FDA Audit: The Research Team s Perspective
1 Effectively Preparing for and Responding to an FDA Audit: The Research Team s Perspective Kate-Louise Gottfried, JD, MSPH, Senior Director Stephanie C. Guzik, RN, BSN, MBA, Assistant Director Research
April 13, Background
Pfizer Inc 235 East 42nd Street New York, NY 10017-5755 Tel 212 733 4210 Fax 646 383 9249 Email: marc.wilenzick@pfizer.com April 13, 2009 http://www.regulations.gov Christine Ireland Committee management
IRB Considerations for Investigator-Initiated Research
November 29, 2017 IRB Considerations for Investigator-Initiated Research Robert Romanchuk, BSHS, CIP, CCRC, CCRP IRB Vice Chair, Schulman IRB Introducing advarra.com About Schulman IRB Established in 1983
1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual Cindy Gates IRB Administration What is the purpose of the INVESTIGATOR MANUAL? The manual is designed
VCU Faculty Held IND and IDE Procedure Handbook
VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted
Conducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
The Johns Hopkins Institute for Clinical and Translational Research
ICTR The Johns Hopkins Institute for Clinical and Translational Research INTRODUCTION TO CLINICALTRIALS.GOV LINDA POST, RN, BSN, CCRP RESEARCH NAVIGATOR JUNE 28, 2013 Development of this resource was supported
4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.
POLICY #: RCO-203 Page: 1 of 7 1. POLICY STATEMENT: Essential regulatory documents will be on maintained for research sponsored by or conducted at Dana-Farber/Harvard Cancer Center (DF/HCC) to assure compliance
OCTC 2012 CRO Selection
OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed
Standard Operating Procedures (SOPs)
Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER
Regulatory Binder Guidance
Regulatory Binder Guidance What is the purpose of a regulatory binder? Achieve and maintain regulatory compliance Ensure protection of human subjects and high standards of research Guidance for organization
U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health
U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE Jeff Shuren Director Center for Devices and Radiological Health 21 ST CENTURY CURES ACT IMPLEMENTATION Provision Implementation activities completed
DEVELOPING CLINICAL TRIALS INFRASTRUCTURE
DEVELOPING CLINICAL TRIALS INFRASTRUCTURE SESSION IV of IOM Workshop: Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020 PAUL EISENBERG PETRA KAUFMANN
Clinical Trials Registration: Your Obligations
Clinical Trials Registration: Your Obligations James Wells, PhD Office of Research Policy Graduate School Shari Zeldin, BS, CCRC UW Comprehensive Cancer Center University of Wisconsin-Madison Committee
Doing Human Subjects Research? Changing NIH Policies May Impact You
Doing Human Subjects Research? Changing NIH Policies May Impact You Reforms & Initiatives To enhance the stewardship of research involving human subjects, NIH is implementing the following: All Research
Toward Greater Transparency and Rigor
Toward Greater Transparency and Rigor TRANSPARENCY: ClinicalTrials.gov registration and results reporting The Center for Clinical & Translational Science 205.934.7442 ccts@uab.edu www.uab.edu/ccts @cctsnetwork
Industry-Sponsored Clinical Trials Improvement Efforts
Industry-Sponsored Clinical Trials Improvement Efforts Update August 10, 2018 Lindsey Criswell Brian Smith Summary of Improvement Workshops Problem Statement: It is essential to decrease the time it takes
HCCA 13 TH ANNUAL COMPLIANCE INSTITUTE LAS VEGAS, NV APRIL 29, 2009
HCCA 13 TH ANNUAL COMPLIANCE INSTITUTE LAS VEGAS, NV APRIL 29, 2009 MEDICARE COVERAGE ANALYSIS WORKSHOP: THE HOW TO OF MEDICARE COVERAGE IN RESEARCH Suzanne LivPage, J.D. Director, Clinical Research Initiation
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug
ClinicalTrials.gov Registration Guide
ClinicalTrials.gov Registration Guide The Food and Drug Administration Amendments Act (FDAAA), National Institutes of Health (NIH) and International Committee of Medical Journal Editors (ICMJE) require
Recommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
Human Research Protection Program Policy
Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may
\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
Becoming Aware of the Requirements Surrounding Clinical Trial Disclosure (ClinicalTrials.gov)
Becoming Aware of the Requirements Surrounding Clinical Trial Disclosure (ClinicalTrials.gov) Office of Research Compliance and Quality Assurance Yolanda P. Davis Sr. Research Compliance Officer Author:
Implementing Good Clinical Practice at an Academic Research Institution
Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of
Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
EU Clinical Trial Regulation A view from the Industry
Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty
TITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19
POLICY #: MULTI-100 Page: 1 of 4 1. POLICY STATEMENT: The DF/HCC Sponsor-Investigator, Coordinating Center and External Sites collaborating in DF/HCC Investigator-Sponsored Multi-Center research must comply
Clinical Trials Office VPR CTO
Clinical Trials Office VPR CTO Velos eresearch Mysti M. Trainer Budget Analyst - Associate Who is the VPR-CTO? Serve Under the Vice President for Research Part of the Research Administration We work closely
Effective Date: October 8, 2015 Policy Number: MHC_RP0301. Corporate Director, HRPP Institutional Official, HRPP
Policy Title: Education and Quality Improvement Program EQuIP Effective Date: October 8, 2015 Policy Number: Review Date: October 8, 2015 Section: Revised Date: Administrative Responsibility: Oversight
ClinicalTrials.gov Registration Guide
ClinicalTrials.gov Registration Guide The Food and Drug Administration Amendments Act (FDAAA), National Institutes of Health (NIH) and International Committee of Medical Journal Editors (ICMJE) require
ClinicalTrials.gov. Why Does it Affect Me? Should I Be Concerned?
ClinicalTrials.gov Why Does it Affect Me? Should I Be Concerned? Meliha Rahmani & Vanessa Hill OSUWMC ClinicalTrials.gov Administrators College of Medicine Office of Research Be aware that Any PowerPoint
Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process
Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process Helene Orescan, J.D. Bishoy Anastasi, MBA, CCRP David Geffen School of Medicine at UCLA Industry Sponsored
Sponsor/Investigator Responsibilities
Sponsor/Investigator Responsibilities Marian Serge, RN Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health Food and Drug Administration Marian.Serge@fda.hhs.gov
and Study Initiation
10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,
and Study Initiation
10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,
HUMAN RESEARCH PROTECTION PROGRAM PLAN
HUMAN RESEARCH PROTECTION PROGRAM PLAN HRP 101 June 2017 706-542-3199 irb@uga.edu https://research.uga.edu/hso/ Table of Contents Scope... 2 Purpose... 2 Definitions... 2 Agent... 2 Clinical Trial... 2
3.0 HSC Relation to Other KUMC Committees
3.0 HSC Relation to Other KUMC Committees It is the policy of the HSC to work in conjunction with other KUMC Committees to provide protections to research subjects. The HSC coordinates reviews with other
A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN
A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN Version 1 - June 2017 A Short Guide For CT Application 1 2 A Short Guide For CT Application DEFINITIONS Clinical
Standard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
Establishment of Clinical Trial Infrastructure
Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan
The In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
Guidelines for Setting Up a Regulatory Binder
Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of
Department At-A-Glance
Integrated Site Services Functional Role Integrated Site Services (ISS) includes global and country Start-Up and Regulatory units (RSU) and Integrated Patients & Site Services (IPSS). Our department s
A Research Compliance Program
A Research Compliance Program We have no financial conflicts of interest The opinions presented here are our own We love building compliance programs Thanks to national research compliance expert Lisa
Clinical Trials Series Part II
Clinical Trials Series Part II Agenda Recap December Presentation J. Schmelz Example: New CT from HSC Investigator Non Cancer Clinical Trial J. Bates, P. Miranda Example: New CT from External Entity Non
ClinicalTrials.gov Updates. Gabrielle Gaspard Assistant Director Human Research Compliance
ClinicalTrials.gov Updates Gabrielle Gaspard Assistant Director Human Research Compliance 02.12.18 1 Posting Requirements for ClinicalTrials.gov Reporting Requirement ICMJE Policy (effective in 2005) FDAAA
1.0 INTRODUCTION AND OVERVIEW
Table of Contents 1.0 INTRODUCTION AND OVERVIEW... 3 2.0 DEFINITIONS... 4 3.0 OVERSIGHT AND ORGANIZATION... 5 3.1 CLINICAL RESEARCH OVERSIGHT COMMITTEE (CROC)... 5 3.2 CLINICAL RESEARCH SUPPORT (CRS)...
TITLE: DF/HCC Investigator-Sponsored Multi-Center TrialsResearch POLICY #: MULTI-100 Page: 11 of 54 Effective Date: 8/31/17 1.
POLICY #: MULTI-100 Page: 11 of 54 1. POLICY STATEMENT: The DF/HCC Sponsor-Investigator, Coordinating Center and External Sites collaborating in DF/HCC Investigator-Sponsored Multi-Center Trialsresearch
SOCIETY OF RESEARCH ADMINISTRATORS ORLANDO FLORIDA OCTOBER 2018
SOCIETY OF RESEARCH ADMINISTRATORS ORLANDO FLORIDA OCTOBER 2018 CLINICAL TRIALS FINANCIAL MANAGEMENT ADMINISTRATIVE CHALLENGES & CONSIDERATIONS Agenda 1. Introduction 2. Challenges in Clinical Trial Financial
Investigational New Drug Development Steps for CRCs
Investigational New Drug Development Steps for CRCs Natalie Nardone, PhD Program Manager, Department of Medicine CRC Instructor, Office of Clinical Research Contact: natalie.nardone@ucsf.edu Learning Objectives
SELF-ASSESSMENT CHECKLIST
SELF-ASSESSMENT CHECKLIST SECTION 1: REGULATORY DOCUMENTATION Staff Documentation 1. Are all versions of the IRB approved protocol on file (including most recent)? 2. Are there CVs/biosketches of PI, Co-Is,
Human Subjects Protection Program Plan
December 1, 2016 HRP-101 12/1/16 2 of 12 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research... 3 Human Research:... 4 Human Subject as Defined
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure
Structuring Compliance: The Duke Model
Structuring Compliance: The Duke Model June 2, 2014 Michael L. Somich, Executive Director, Office of Internal Audits Tina R. Tyson, JD, Chief Ethics and Compliance Officer What is a Compliance Program?
Structuring Compliance: The Duke Model
Structuring Compliance: The Duke Model June 2, 2014 Michael L. Somich, Executive Director, Office of Internal Audits Tina R. Tyson, JD, Chief Ethics and Compliance Officer What is a Compliance Program?
Clinical Trial Disclosure: Current US Situation
Clinical Trial Disclosure: Current US Situation 1 Huron Consulting Group Inc. All rights reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,
COI V September Draft. USC Conflict of Interest Disclosure System (COIDS) System Requirements V1.0 (Draft)
USC Conflict of Interest Disclosure System () System Requirements V1.0 (Draft) September 18, 2011 1 1. Purpose and Scope This document provides the requirements for a Conflict of Interest Disclosure System
1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
Clinical Research at MSU
Financial Administration Development Program: Clinical Research at MSU Kristen Burt, Office of Regulatory Affairs (ORA) Sharon Schooley, Clinical & Translational Sciences Institute (CTSI) February 24,
Good Clinical Practice Compliance
Good Clinical Practice Compliance Pharmaceutical Regulatory & Compliance Congress Greg Levine LLP Agenda? GCP compliance rules What is the law? What other (non-binding) standards apply? What are the unwritten
MCRA Clinical More Than Your Average CRO. Clinical Project Management. Site Management and Study Monitoring. Data Management. Auxiliary Services
MCRA s unique Clinical Research Organization (CRO) enables international and US-based orthopedic companies of all sizes to successfully execute a clinical study. Our philosophy is to streamline the clinical
Compliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
The Research Services Organization (RSO) of the Academic Health Center
Annual Report 2005 The Research Services Organization (RSO) of the Academic Health Center A Summary of the Eighth Year of Operations Submitted by: Mark S. Paller, M.D., M.S. Director, Research Services
CDER Perspective: Good Clinical Practice
CDER Perspective: Good Clinical Practice Sensible Guidelines Symposium, 25 May 2012 Ann Meeker-O Connell FDA, CDER, Office of Compliance Office of Scientific Investigations The views presented in this
Melanie Hawkins, BSN, RN, CCRC Director, Clinical Research Billing Compliance Kristin Pattee Couture, CCRP Clinical Research Coverage Analyst
NEW CLINICAL RESEARCH BILLING SCHEDULE Melanie Hawkins, BSN, RN, CCRC Director, Clinical Research Billing Compliance Kristin Pattee Couture, CCRP Clinical Research Coverage Analyst What is a billing schedule
ClinicalTrials.gov Registration and Results Reporting: Updates and Recent Activity
Vol. 7, No. 2, February 2011 Can You Handle the Truth? ClinicalTrials.gov Registration and Results Reporting: Updates and Recent Activity By Matthew Lester and Barbara Godlew The Food and Drug Administration
CAPA Management: Best Practices and FDA QSR Mandate WHITE PAPER. ComplianceQuest In-Depth Analysis and Review
CAPA Management: Best Practices and FDA QSR Mandate WHITE PAPER ComplianceQuest In-Depth Analysis and Review CAPA Management: Best Practices and FDA QSR Mandate Establishing a corrective and preventive
Why Industry Collaborations Matter TransCelerate BioPharma, Inc.
Why Industry Collaborations Matter TransCelerate BioPharma, Inc. Jackie Kent Eli Lilly & Co. Shared Investigator Platform Initiative Leader, TransCelerate BioPharma Inc. Introduced by: Carlo Maccarrone
Standard Operating Procedure
Standard Operating Procedure Number: UM/UoM TMF/SOP08/6.0 Title: The Creation and Maintenance of Trial Master Files and Essential Documentation Version: 6.0 () Effective Date: Author: Mrs Catherine Barrow
Investigational New Drug (IND) & Investigational Device Exemptions (IDE) Applications Preparation and Submission, and Conducting FDA Meetings
Investigational New Drug (IND) & Investigational Device Exemptions (IDE) Applications Preparation and Submission, and Conducting FDA Meetings *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER
NIH Policy on Dissemination of NIH- Funded Clinical Trial Information
NIH Policy on Dissemination of NIH- Funded Clinical Trial Information Valery Gordon, Ph.D., M.P.H. Senior Advisor for Human Subjects Protection Division of Clinical Innovation 2018 Spring CTSA Program
August 3, 2017 Closeout Management. UNC Symposium for Research Administrators
August 3, 2017 Closeout Management UNC Symposium for Research Administrators UNC Symposium for Research Administrators Presenters Jennifer Gwaltney Assistant Director Sponsored Projects Accounting Office
The Brave New World of Medical Devices
The Brave New World of Medical Devices December 17, 2014 BOSTON GERMANY ISRAEL www.bmtadvisors.com www.bmtcrogroup.com 1 It Is All About The Adoption More Than a Mantra David Barone December 17, 2014 www.bmtadvisors.com
Regulatory Binder: Set-up and Maintenance
Regulatory Binder: Set-up and Maintenance Introduction Federal and state regulations, institutional policy, and good clinical and research practices require investigators to maintain documents related
ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc.
ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc. 25 October 2017: University of Rochester Achieving High Quality Clinical Research
Good Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
Strasser, Jane (strassje)
Strasser, Jane (strassje) From: Strasser, Jane (strassje) Sent: Tuesday, April 12, 2011 11:35 AM To: UC-COMP-MATTERS@LISTSERV.UC.EDU Subject: [UC-COMP-MATTERS] Compliance Matters--April
What you missed at the: 2 nd Clinical Trials Inspection Readiness Summit August 2013 Philadelphia, PA
What you missed at the: 2 nd Clinical Trials Inspection Readiness Summit August 2013 Philadelphia, PA For a complete overview download the 2013 Executive Summary Notice of Inspection US FDA European Regulatory
Human Research Protection Program. Plan
Human Research Protection Program Plan Revised September 6, 2017 HRP-101 9/6/17 2 of 13 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...
Guidance for IRBs, Clinical Investigators and Sponsors
Guidance for IRBs, Clinical Investigators and Sponsors IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is